Literature DB >> 29249207

Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less "go" and more "stop" from the motor striatum for robust therapeutic effects.

Stephen M Stahl.   

Abstract

Tardive dyskinesia can now be successfully treated by inhibiting the vesicular monoamine transporter type 2 (VMAT2).

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29249207     DOI： 10.1017/S1092852917000621

Source DB:  PubMed          Journal:  CNS Spectr        ISSN： 1092-8529            Impact factor:   3.790


  4 in total

Review 1.  Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.

Authors:  Nicki Niemann; Joseph Jankovic
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

2.  [Antipsychotic-induced motor symptoms in schizophrenic psychoses-Part 3 : Tardive dyskinesia].

Authors:  D Hirjak; K M Kubera; S Bienentreu; P A Thomann; R C Wolf
Journal:  Nervenarzt       Date:  2019-05       Impact factor: 1.214

Review 3.  Valbenazine for the Treatment of Adults with Tardive Dyskinesia.

Authors:  Harshit Gupta; Alycee R Moity; Allison Jumonville; Sarah Kaufman; Amber N Edinoff; Alan D Kaye
Journal:  Health Psychol Res       Date:  2021-06-18

Review 4.  Recent Discussions on Dopamine Supersensitivity Psychosis: Eight Points to Consider When Diagnosing Treatment-Resistant Schizophrenia.

Authors:  Nobuhisa Kanahara; Hiroshi Kimura; Yasunori Oda; Fumiaki Ito; Masaomi Iyo
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.